Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

被引：6
|
作者：
Smyth, Elizabeth Catherine
Turner, Nicholas C.
Pearson, Alex
Peckitt, Clare
Chau, Ian
Watkins, David J.
Starling, Naureen
Rao, Sheela
Gillbanks, Angela
Kilgour, Elaine
Sumpter, Katherine Anne
Smith, Neil R.
Cutts, Ros
Rooney, Claire
Thomas, Anne L.
Ajaz, Mazhar A.
Chua, Sue
Brown, Gina
Popat, Sanjay
Cunningham, David
机构：
[1] Royal Marsden, London, England
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden Hosp, London SW3 6JJ, England
[4] AstraZeneca Oncol Innovat Med, Macclesfield, Cheshire, England
[5] Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[6] Leicester Royal Infirm, Leicester, Leics, England
[7] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
154
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Llimpe, F. L. Rojas
    Ceccarelli, C.
    Mutri, V.
    Giaquinta, S.
    Piana, E.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S
  • [42] SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
    Aggarwal, Charu
    Redman, Mary W.
    Lara, Primo N., Jr.
    Borghaei, Hossein
    Hoffman, Philip
    Bradley, Jeffrey D.
    Newman, Alfred J., III
    Feldman, Marvin J.
    Minichiello, Katherine
    Miao, Jieling
    Mack, Philip C.
    Papadimitrakopoulou, Vassiliki A.
    Herbst, Roy S.
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1847 - 1852
  • [43] Phase I-II study concomitant taxol and carboplatin with radiotherapy in advanced head and neck cancer.: Preliminary results.
    Jaén, A
    Martos, M
    González, E
    Medina, B
    Sánchez, P
    Cabrero, A
    Porras, I
    Mohedano, N
    Capllonch, M
    Fernández, M
    Lozano, A
    Casanova, MA
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S62 - S62
  • [44] A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results.
    Buzdar, A
    Silverman, P
    Kaufman, PA
    Waintraub, S
    Doyle, T
    Kroener, J
    Robinson, P
    Perez, E
    Zhang, X
    DeMario, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S69 - S69
  • [45] Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group
    Arnold, D.
    Thuss-Patience, P. C.
    Stein, A.
    Grothe, W.
    Seufferlein, T.
    Reinacher-Schick, A.
    Geisaler, M.
    Hofheinz, R.
    Moehler, M. H.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Nag, S.
    Chow, L. W.
    Chang, P. C.
    Ahmad, N. M.
    Berger, M.
    Arbushites, M.
    Westlund, R.
    Stanislaus, M.
    Zaks, T.
    Stein, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [47] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy:: FISH results.
    Felip, E.
    Rojo, F.
    Reck, M.
    Heller, A.
    Klughammer, B.
    Maacke, H.
    Möcks, J.
    Brennscheidt, U.
    Gatzemeier, U.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 404S - 404S
  • [48] Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
    Alessandra Fabi
    Giulio Metro
    Paola Papaldo
    Marcella Mottolese
    Elisa Melucci
    Paolo Carlini
    Isabella Sperduti
    Michelangelo Russillo
    Alain Gelibter
    Gianluigi Ferretti
    Silverio Tomao
    Michele Milella
    Francesco Cognetti
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 717 - 725
  • [49] Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
    Fabi, Alessandra
    Metro, Giulio
    Papaldo, Paola
    Mottolese, Marcella
    Melucci, Elisa
    Carlini, Paolo
    Sperduti, Isabella
    Russillo, Michelangelo
    Gelibter, Alain
    Ferretti, Gianluigi
    Tomao, Silverio
    Milella, Michele
    Cognetti, Francesco
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) : 717 - 725
  • [50] Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
12345